Last reviewed · How we verify
Guangzhou Zhiyi Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Live SK08 powder | Live SK08 powder | phase 3 | Live attenuated vaccine | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bandim Health Project · 1 shared drug class
- Beijing Center for Disease Control and Prevention · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- Canadian Immunization Research Network · 1 shared drug class
- Center for Research and Production of Vaccines and Biologicals, Vietnam · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- Changchun BCHT Biotechnology Co. · 1 shared drug class
- Aga Khan University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Guangzhou Zhiyi Biotechnology Co., Ltd.:
- Guangzhou Zhiyi Biotechnology Co., Ltd. pipeline updates — RSS
- Guangzhou Zhiyi Biotechnology Co., Ltd. pipeline updates — Atom
- Guangzhou Zhiyi Biotechnology Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Guangzhou Zhiyi Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangzhou-zhiyi-biotechnology-co-ltd. Accessed 2026-05-17.